http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Ogata, Sho,Yasuhara, Hideaki,Kinoshita, Naoki,Cheon, Dae-Sung,Kishida, Kiyoshi Elsevier 2018 International journal of rock mechanics and mining Vol.107 No.-
<P><B>Abstract</B></P> <P>A multi-physics numerical model was developed to predict the fluid flow and mass transport behavior of rock fractures under coupled thermal-hydraulic-mechanical-chemical (THMC) conditions. In particular, the model was employed for the purpose of describing the evolution of permeability and reactive transport behavior within rock fractures by taking into account the geochemical processes of the free-face dissolution and the pressure dissolution. In order to examine the capability of the developed model, the model was applied to replicate the experimental measurements of the evolution in hydraulic aperture, permeability, and element concentrations obtained from two flow-through experiments using single granite and mudstone fractures. The model predictions for the granite experiment were able to follow the actual data for the evolution in hydraulic aperture and effluent element concentrations without adopting any fitting parameters that are often used in other THMC coupled models obtained from literature. Furthermore, the model succeeded in replicating the actual changes in fracture permeability and effluent element concentrations within the mudstone fracture. Although some uncertain mismatches between the experiments and the model predictions, such as changes in the concentrations of several elements (i.e., Na and K concentrations in the granite fracture and Al in the mudstone fracture) were remaining at this stage, the developed model should be valid for evaluating the evolution in the fluid flow and mass transport behavior within rock fractures induced by mineral dissolution under stress- and temperature-controlled conditions.</P> <P><B>Highlights</B></P> <P> <UL> <LI> A coupled THMC numerical model was developed to predict changes in the permeability and reactive transport behavior within single rock fractures. </LI> <LI> The model was validated by replicating experimental measurements using granite and mudstone fractures. </LI> <LI> There were, however, some uncertain mismatches between the experiments and the model predictions in the concentrations of several elements. </LI> </UL> </P>
Ogata, Alana F.,Song, Seok-Won,Cho, Su-Ho,Koo, Won-Tae,Jang, Ji-Soo,Jeong, Yong Jin,Kim, Min-Hyeok,Cheong, Jun Young,Penner, Reginald M.,Kim, Il-Doo American Chemical Society 2018 ANALYTICAL CHEMISTRY - Vol.90 No.15
<P>A new type of chemiresistor, the impedance-transduced chemiresistor (ITCR), is described for the rapid analysis of glucose. The ITCR exploits porous, high surface area, fluorine-doped carbon nanofibers prepared by electrospinning of fluorinated polymer nanofibers followed by pyrolysis. These nanofibers are functionalized with a boronic acid receptor and stabilized by Nafion to form the ITCR channel for glucose detection. The recognition and binding of glucose by the ITCR is detected by measuring its electrical impedance at a single frequency. The analysis frequency is selected by measuring the signal-to-noise (<I>S</I>/<I>N</I>) for glucose detection across 5 orders of magnitude, evaluating both the imaginary and real components of the complex impedance. On the basis of this analysis, an optimal frequency of 13 kHz is selected for glucose detection, yielding an <I>S</I>/<I>N</I> ratio of 60-100 for [glucose] = 5 mM using the change in the total impedance, Δ<I>Z</I>. The resulting ITCR glucose sensor shows a rapid analysis time (<8 s), low coefficient of variation for a series of sensors (<10%), an analysis range of 50 μM to 5 mM, and excellent specificity versus fructose, ascorbic acid, and uric acid. These metrics for the ITCR are obtained using a sample size as small as 5 μL.</P> [FIG OMISSION]</BR>
( Haruhiko Ogata ),( Tadashi Yokoyama ),( Seiichi Mizushima ),( Atsushi Hagino ),( Toshifumi Hibi ) 대한장연구학회 2018 Intestinal Research Vol.16 No.2
Background/Aims: This study compared the efficacy of multimatrix mesalazine 2.4 g/day and 4.8 g/day with controlled-release mesalazine 2.25 g/day. Methods: In this multicenter, randomized, double-blind study, 251 patients with mildly to moderately active ulcerative colitis received multimatrix mesalazine 2.4 g/day once daily (Multimatrix-2.4), 4.8 g/day once daily (Multimatrix-4.8), or controlled-release (time-dependent) mesalazine 2.25 g/day 3 times daily (Time-2.25) for 8 weeks. The primary efficacy endpoint was the change in the ulcerative colitis-disease activity index (UC-DAI) score. Results: The mean change in the UC-DAI score and standard deviation in the per protocol set was -1.9±2.5 for Multimatrix-2.4 and -2.4±2.8 for Time-2.25. The difference between Multimatrix-2.4 and Time-2.25 was 0.3 (two-sided 95% confidence interval [CI], -0.5 to 1.1), thus non-inferiority was not demonstrated based on the pre-defined non-inferiority margin (1.0). In the full analysis set, the difference between Multimatrix-4.8 and Time-2.25 was -1.2 (two-sided 95% CI, -2.0 to -0.5), and the mean change in UC-DAI score in the FAS was -3.3 (two-sided 95% CI, -3.9 to -2.8) for Multimatrix-4.8 and -1.9 (two-sided 95% CI, -2.5 to -1.3) for Multimatrix-2.4, indicating that Multimatrix-4.8 was more effective than Time-2.25 and Multimatrix-2.4. There was no difference among the treatment groups in terms of safety. Conclusions: This study showed that the efficacy of multimatrix mesalazine 2.4 g/day was comparable to controlled release mesalazine 2.25 g/day, although non-inferiority was not demonstrated. Importantly, this was the first study to indicate that multimatrix mesalazine 4.8 g/day was more effective than 2.4g/day with no associated safety concerns. (Intest Res 2018;16:255-266)
( Haruhiko Ogata ),( Nobuo Aoyama ),( Seiichi Mizushima ),( Atsushi Hagino ),( Toshifumi Hibi ) 대한장연구학회 2017 Intestinal Research Vol.15 No.3
Background/Aims: This study assessed the efficacy and safety of high-dose multimatrix mesalazine once-daily (QD) compared to another form of high-dose mesalazine. Methods: In this multicenter, randomized, double-blind study, 280 patients with mildly to moderately active ulcerative colitis (UC) received multimatrix mesalazine 4.8 g/day QD or pH-dependentrelease mesalazine 3.6 g/day three times daily for 8 weeks. The primary endpoint was the change in the UC-Disease Activity Index (UC-DAI) at the end of the treatment period. Results: The change in the UC-DAI (mean±standard deviation) in the perprotocol set was -2.6±2.47 in the multimatrix mesalazine 4.8 g/day group (n=134) and -1.8±2.64 in the pH-dependent-release mesalazine 3.6 g/day group (n=129). The difference in the mean change between the 2 groups was -0.7 (two-sided 95% confidence interval, -1.3 to -0.1). The noninferiority of multimatrix mesalazine 4.8 g/day to pH-dependent-release mesalazine 3.6 g/ day was verified within the noninferiority margin (1.1). The superiority of multimatrix mesalazine 4.8 g/day to pH-dependentrelease mesalazine 3.6 g/day was also investigated and confirmed in the full analysis set, according to the study protocol. In subgroup analyses, the effectiveness of multimatrix mesalazine 4.8 g/day was consistent in all subgroups. There was no difference in safety between the 2 treatment groups. Conclusions: Multimatrix mesalazine 4.8 g/day has higher efficacy and shows no difference in safety in mildly to moderately active UC, in comparison with pH-dependent-release mesalazine 3.6 g/day. (Intest Res 2017;15:368-379)
( Haruhiko Ogata ),( Takashi Hagiwara ),( Takeshi Kawaberi ),( Mariko Kobayashi ),( Toshifumi Hibi ) 대한장연구학회 2021 Intestinal Research Vol.19 No.4
Background/Aims: Adalimumab has been shown to induce and maintain clinical remission in patients with moderate to se-vere ulcerative colitis (UC). However, no large-scale population-based studies have been performed in Japan. This study was conducted to evaluate the safety and effectiveness of adalimumab in clinical practice in Japanese patients with UC. Methods: In this 52-week, prospective, multicenter, single-cohort, noninterventional, observational, postmarketing surveillance study, patients with moderate to severe UC received an initial subcutaneous injection of adalimumab 160 mg, followed by 80 mg at 2 weeks, and then 40 mg every other week. Safety assessments were the incidence of adverse drug reactions (ADRs) and seri-ous ADRs. Effectiveness assessments were clinical remission, corticosteroid-free remission, mucosal healing, and change in C-reactive protein (CRP) levels from baseline. Results: Of 1,593 registered patients, 1,523 (male, 57.6%; mean age, 41.8 years) and 1,241 patients were included in the safety and effectiveness populations, respectively. ADRs were reported in 18.1% and serious ADRs in 4.9% of patients. Clinical remission was achieved in 49.7% of patients at week 4, increasing to 74.4% at week 52. Corticosteroid-free remission rates increased over time, from 10.4% at week 4 to 53.1% at week 52. More than 60% of patients demonstrated mucosal healing at weeks 24 and 52. Mean CRP levels (mg/dL) decreased from 1.2 at baseline to 0.6 at week 4 and 0.3 at week 52. Conclusions: This large real-world study confirmed the safety and effectiveness of adalimumab in patients with UC in Japan. No new safety concerns were identified. (Intest Res 2021;19:419-429)